

VioQuest Pharmaceuticals, Inc.  
Form 8-K  
October 27, 2008

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

**FORM 8-K**

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 24, 2008

**VioQuest Pharmaceuticals, Inc.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**000-16686**  
(Commission File Number)

**58-1486040**  
(IRS Employer  
Identification No.)

**180 Mt. Airy Road, Suite 102**  
**Basking Ridge, NJ 07920**  
(Address of principal executive offices)

**(908) 766-4400**  
(Registrant's telephone number, including area code)

**N/A**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02**

**Departure of Directors or Certain Officers.**

On October 24, 2008, VioQuest Pharmaceuticals, Inc. (the “Company”) provided a strategic alternatives review and operations update and released the press release filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and the press release is incorporated herein by reference.

**Item 8.01**

**Other Events.**

On October 24, 2008, the Company provided a strategic alternatives review and operations update and released the press release filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and the press release is incorporated herein by reference.

**Item 9.01**

**Financial Statements and Exhibits.**

(d)

*Exhibits*

Exhibit No.	Description
99.1	Press release of the Company dated October 24, 2008.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**VioQuest Pharmaceuticals, Inc.**

Date: October 27, 2008

By: /s/ Christopher P. Schnittker  
Christopher P. Schnittker  
Vice President &  
Chief Financial Officer

---